Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 4

Conditions: Heart Failure, Congestive

Treatments: Drug: ACE inhibitors; Drug: Beta-blockers including Carvedilol

Study type: Interventional

Funder types: Industry

Identifiers

NCT00344513

105517/358

Details and patient eligibility

About

This program is designed to improve medical care and education of hospitalized patients with heart failure and accelerate the initiation of evidence-based heart failure guideline recommended therapies by administering them before hospital discharge. A registry component focusing on admission to discharge and 60- to 90-day follow-up is designed to evaluate the demographic, pathophysiologic, clinical, treatment, and outcome characteristics of patients hospitalized with heart failure.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hospitalized for episode of worsening heart failure as primary cause of admission or significant heart failure symptoms that develop during the hospitalization when the initial reason for admission was not heart failure.
• Systolic dysfunction (LVEF < 40%) or heart failure symptoms in the setting of preserved systolic function (diastolic dysfunction).

Exclusion criteria

• This study has no exclusion criteria.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)